Tamim Niazi, MDCM, of McGill University, discusses phase III study findings on hypofractionated, dose-escalation radiation therapy for high-risk adenocarcinoma of the prostate (Abstract 281).
Marcus E. Randall, MD, of the University of Kentucky, discusses phase III study findings on pelvic radiation therapy vs vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early stage endometrial cancer (Abstract LBA1).
Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer after external-beam radiation therapy (Abstract 1).
William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, and surgery in men with high-risk, nonmetastatic adenocarcinoma of the prostate (Abstract 15).
Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using chemotherapy instead of radiation in early-stage seminoma; radiotherapy vs surgery plus radiotherapy in Gleason score 9–10 prostate cancer; and an analysis of the IROCK study on kidney cancer (Abstracts 1, 1089, 282, 330).
Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II findings show this approach may be effective in light of improved systemic treatment and better chemotherapy response assessment (Presentation 298).
